Familial clustering of colorectal cancer (CRC) was first reported in 1904.' Lovett identified a two to fourfold increase in the expected death rate in a study of mortality cause among first degree relatives of CRC patients. 2 The CRC incidence among relatives of patients affected by apparently sporadic disease has similarly been shown to be four times that expected. 3 Screening studies in Israel,4 in the USA,5 6 and in the United Kingdom,7 8 have confirmed the tendency for a familial inheritance of colorectal adenomas in those not affected by well defined CRC syndromes.
Most screening protocols for subjects at increased risk because of a family history of CRC include faecal occult blood testing (FOBT) and flexible sigmoidoscopy for all. If a particularly strong family history is evident,4 8 colonoscopy is the first choice investigation because of the increased prevalence of right colonic neoplasia in dominantly inherited pedigrees. 7 Colonoscopy is the first choice investigation after positive FOBTs.
We have been offering screening to subjects with first degree relatives affected by CRC since 1992. We aimed to establish the significance of a family history of CRC in asymptomatic relatives in a district hospital and, in this setting, to establish if screening asymptomatic family members from 25 years is worthwhile. We have attempted to validate family history based screening in a protocol that does not include flexible sigmoidoscopy for all those screened. We have tried to inform those with a family history of CRC of its significance and we have informed them of the important symptoms of the disease.
Methods
Potential subjects for screening over age 25 were identified by contacting relatives of past CRC patients whose details have been maintained on a database since 1979. At first, contacts were made for those still living but later, relatives of dead patients were included. Index subjects were initially chosen at random. Later, those who had developed the disease aged less than 45 were targeted; the relatives of young index cases are at relatively high risk and we aimed to contact people expected to gain most from screening (Table I) (Table I).7  Table II summarises the screening policy. If lifetime risk was <1:10, the FOBT negative This report deals with the results of a CRC screening study at a single point in the lifetime of subjects considered to be at a higher than average risk of developing the disease. Because the inherited increased risk is effective over the whole lifetime, the true impact of such screening will only be seen after a much longer time interval. The results of the study are presented with this in mind. Figure 1 shows the age proportions of the subjects who were screened. All patients have had only one colonoscopy to date; the number of colonoscopies undertaken in each age group is shown in the Figure. Lifetime risk Figure 3 shows the breakdown of lifetime risk. Some 59.6% of those who completed the protocol had only one affected relative. The smallest group contained people with three or more affected first degree relatives; only four subjects from two families were potentially in a dominant pedigree. Table IV shows the characteristics of the adenomas detected by our programme.
Results

Subjects screened
If single adenomas less than 1 cm in size have minimal risk of malignancy or early malignant transformation, seven of 12 adenomas detected were of immediate clinical significance. Most important is the 64 year old diagnosed with familial adenomatous polyposis who had one first degree relative affected by both CRC and periampullary carcinoma. This patient had a large caecal villous adenoma and more than 300 smaller adenomas and, after surgery, has been counselled by a medical geneticist. Two people, aged 65 and 68, had dysplastic rectal adenomas larger than 5 cm.
One of four adenomas diagnosed in those younger than 55 was larger than 1 cm. Sixty three colonoscopies carried out in this age group represented 68l1% of the endoscopic workload. Six of eight adenomas detected in those older than 55 were larger than 1 cm and only 28 colonoscopies were needed to diagnose these.
One adenoma (which was diminutive) would not have been detected by flexible sigmoidoscopy. This 31 year old had recorded a negative FOBT but was examined because of a mistaken interpretation of her estimated lifetime risk on initial assessment, which was subsequently revised. All other subjects had adenomas that would readily have been diagnosed by flexible sigmoidoscopy.
Discussion
We have deviated from the usual family history based screening protocol, largely because of flaws in the chemistry of guaiac FOBTs that limit their sensitivity and specificity. 10 11 Haemoccult has performed poorly in population based screening studies detecting 38-50% Although HemeSelect is unproved in screening for asymptomatic colonic neoplasia, to commence screening by our protocol using a guaiac FOBT would have risked missing significant abnormality in those with a single first degree affected relative.
We have also deviated from the format of other screening programmes in the choice of colonoscopy rather than flexible sigmoidoscopy as the mainstay of colonic examination. Others have shown that flexible sigmoidoscopy is satisfactory for colonic examination in those with only one first degree relative.18 19 We expected the pattern of family history to resemble that of the St Mark's Hospital family cancer screening clinic where people with young affected relatives and those with more than one affected family member were specifically targeted. The Guildford survey aimed at screening a similar population and found 65 subjects from 43 families in possible dominant pedigrees. 20 We also sought to include those with higher lifetime risks and were surprised to find that so few of our group were in such pedigrees. The difference between the two studies is dramatic and may warrant further analysis, but despite this, the adenoma yield was similar. We now agree that it would have been reasonable to use flexible sigmoidoscopy as the usual method of endoscopy in all subjects (except for a positive FOBT or dominant pedigree), with follow up colonoscopy as appropriate. This approach would have been easier and cheaper in terms of endoscopic commitment.
The age at which to begin screening is somewhat arbitrary. We chose age 25 and Carpenter chose age 30.20 We started at this age because of our expectations of the likely family history pattern, which did not materialise. Outwith dominant pedigrees, we now consider age 40 (or 15 years younger than the index case) to be appropriate to start endoscopic screening; below this age CRC is rare.
Adenomas were diagnosed in 12 of 91 subjects who had a colonoscopy (13.2%). The age range of the study group indicates that approximately 25 subjects would have been expected to bear adenomas (Table V) .21 It is difficult to predict the number of large adenomas expected in our population. The youth of the screened group may explain why so few were detected. We have, however, diagnosed at least three people who had adenomas likely to undergo early malignant transformation. We were not surprised that a carcinoma was not found in this small group.
These results provide evidence to support the further assessment of the immunological FOBT in CRC screening, perhaps as a comparison between single and three slide tests. We are considering redirecting money saved by undertaking fewer colonoscopies to more frequent -that is, -annual FOB testing.
There is a demand, among first degree relatives of CRC patients, for counselling and examination to assess their risk of developing the disease.20 The well defined CRC syndromes make up only 10-20% of all cases and advances in genetic testing are unlikely to have an immediate impact on the incidence of most cancers. Until the familial colon cancer genes are further characterised, genetic screening for families and others not in definite inheritance pedigrees is an unrealised objective. Demand for programmes to identify and treat these patients will remain.22 Our study, and the Guildford one,20 will have included examples of sporadic CRC despite attempts to target high risk pedigrees. For this reason, family screening clinics will have a limited impact on sporadic CRC and the role of the specific FOBT in, and outside, such protocols is especially important.
The cost of screening to date, including secretarial support, HemeSelect tests, and colonoscopy is estimated at £ 19 630. Each adenoma detected cost approximately £1630 (or £6540 for each of the three more significant adenomas). The major expenditure was for day case colonoscopy, which could have been reduced had flexible sigmoidoscopy been preferred for colonic examination. These costs are similar to those incurred at Guildford and the low yield from this outlay is comparable.20
Similarly, the benefit of reassurance given to a large number of people is unquantifiable.
We have screened first degree relatives of subjects affected by CRC in a district hospital setting, using a novel protocol to good effect. In the light of our results, some recommendations for others proposing to establish a similar service are shown in Table VI 
